| P50 | author | Jaebok Choi | Q52430559 |
| P2093 | author name string | John F DiPersio | |
| | Karl Staser | |
| | Mark A Schroeder | |
| P2860 | cites work | Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission | Q24539030 |
| | Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases | Q26775111 |
| | The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease | Q28076264 |
| | CCL3, acting via the chemokine receptor CCR5, leads to independent activation of Janus kinase 2 (JAK2) and Gi proteins | Q33292191 |
| | Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients | Q33440405 |
| | Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation | Q33600093 |
| | High levels of B-cell activating factor in patients with active chronic graft-versus-host disease | Q34135089 |
| | Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect | Q34301568 |
| | CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. | Q34311645 |
| | Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. | Q34420372 |
| | Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD | Q34974093 |
| | National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report | Q35085226 |
| | A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study | Q35120338 |
| | Ibrutinib treatment ameliorates murine chronic graft-versus-host disease | Q35140097 |
| | Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen | Q35553626 |
| | Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells | Q35668303 |
| | Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease | Q35848361 |
| | CCR2 is required for CD8-induced graft-versus-host disease. | Q35848441 |
| | Prevention of graft versus host disease by inactivation of host antigen-presenting cells | Q78016071 |
| | CD4+ T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease | Q80819729 |
| | A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses | Q81357571 |
| | The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells | Q85648921 |
| | Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 |
| | Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease | Q35865094 |
| | Advances in understanding the pathogenesis of graft-versus-host disease | Q35971439 |
| | First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation | Q36113205 |
| | IFNγR signaling mediates alloreactive T-cell trafficking and GVHD | Q36395621 |
| | Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors | Q36675937 |
| | Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 |
| | B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. | Q36863150 |
| | SOCS1 regulates CCR7 expression and migration of CD4+ T cells into peripheral tissues | Q36874342 |
| | Interleukin-2 and regulatory T cells in graft-versus-host disease | Q37055805 |
| | Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells | Q37104254 |
| | Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial | Q37113099 |
| | Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma | Q37222679 |
| | Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation | Q37371294 |
| | Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib | Q37652919 |
| | The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights | Q37732574 |
| | Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer | Q37773234 |
| | Targeting JAK kinase in solid tumors: emerging opportunities and challenges | Q38485889 |
| | Chronic graft-versus-host disease: biological insights from preclinical and clinical studies | Q39002164 |
| | Novel targets in the treatment of chronic graft-versus-host disease | Q39023963 |
| | Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway | Q39315794 |
| | Differential requirements for JAK2 and TYK2 in T cell proliferation and IFN-gamma production induced by IL-12 alone or together with IL-18. | Q40669473 |
| | Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects | Q40936847 |
| | Graft-versus-leukemia reactions after bone marrow transplantation | Q41198977 |
| | Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors | Q41893567 |
| | Ruxolitinib in steroid refractory graft-vs.-host disease: a case report | Q42255208 |
| | The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 |
| | HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. | Q44458617 |
| | Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease | Q44925138 |
| | Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning | Q47231959 |
| | Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation | Q47804369 |
| | Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy | Q49679320 |
| | Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease | Q50069438 |
| | Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. | Q50798708 |
| | Ruxolitinib treatment for GvHD in patients with myelofibrosis. | Q51411675 |
| | Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. | Q54327095 |
| | Diagnosis and management of chronic graft-versus-host disease | Q56963759 |
| | Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease | Q57917586 |
| | Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice | Q74420476 |
| | Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase | Q74456595 |
| P433 | issue | 6 | |
| P304 | page(s) | 1125-1134 | |
| P577 | publication date | 2017-12-28 | |
| P1433 | published in | Biology of Blood and Marrow Transplantation | Q15754328 |
| P1476 | title | The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia | |
| P478 | volume | 24 | |